CDK4/6 inhibitors in advanced breast cancer, what is beyond?
Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2-...
| 發表在: | Oncology Reviews |
|---|---|
| Main Authors: | , , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
Frontiers Media S.A.
2019-07-01
|
| 主題: | |
| 在線閱讀: | https://www.oncologyreviews.org/index.php/or/article/view/416 |